Filter posts

Treating Hepatitis C: Too Costly Not to Act

Today, The Hill published an op-ed – Treating hepatitis C: Too costly not to act …

Partners for Healthy Dialogues: Letter to CMS

BIO, a member of Partners for Healthy Dialogues (P4HD), joined 25 medical societies and manufacturers in …

New Report: Innovation in Hepatitis C Treatment

Today, the California Healthcare Institute released a report on the public health impact of Hepatitis …

BioCentury TV This Week: 340B Drug Discount Program Needs More Oversight

BIO’s Laurel Todd shared concerns that the 340B program has departed significantly from its original …

Beggar-Thy-Neighbor Medicine: Wall Street Journal Op-Ed

In an editorial about specialty drug prices, the Wall Street Journal writes: “To understand how …

The Cancer Death-Panel App

In an article for the New York Post, Robert Goldberg, vice president of the Center …

AIR 340B New Report: Contract Pharmacy Growth in 340B

Today, the Alliance for Integrity and Reform of 340B (AIR 340B) released a white paper …

Exchange Plans are Helping Patients, But Challenges Remain

After describing many of the benefits the Exchanges have brought to patients—including access to both …

Making the Case for Personalized Medicine

Personalized medicine is the customization of healthcare. Already, a suite of molecular approaches is being …

NIH, Patients and Industry Ramp Up to AMP-lify Innovation

Speakers at Wednesday’s BIO 2014 Super Session – AMP-lifying Innovation: NIH, Patient Organizations & Leading …